Full-Time
Develops Prime Editing gene therapies
$131k - $146k/yr
Cambridge, MA, USA
In Person
PhD
See people who can refer or advise you
Prime Medicine develops gene-editing therapies designed to treat a wide range of genetic diseases. The company utilizes a specific technology called "Prime Editing," which acts like a DNA word processor. This system can search for a specific location in the genetic code and replace a faulty segment of DNA with a corrected version, restoring normal function to the gene. Unlike earlier gene-editing methods like CRISPR-Cas9, which often create double-stranded breaks in DNA that can lead to unpredictable insertions or deletions, Prime Editing makes precise changes without breaking both strands of the DNA helix. This approach allows for more control over the final genetic sequence and reduces the risk of unintended mutations. The company’s goal is to create one-time curative treatments that can halt or prevent genetic disorders, providing lifelong health benefits to patients by addressing the root cause of their conditions at the molecular level.
Company Size
51-200
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2019
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Flexible Work Hours
Beam Therapeutics (NASDAQ: BEAM) and Ionis Pharmaceuticals (NASDAQ: IONS): two different competitive setbacks hit biotech names in same week. 11 July 2026 06:36 AM PDT Summarize with AI You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to its research reports, in-depth technical and fundamental research. Learn more Key Highlights * Beam Faces Competitive Threat in AATD From Prime Medicine Arbitration Win: Arbitration awarding Prime Medicine the right to develop PM647 creates competitive uncertainty in Beam's key AATD program. * Ionis Loses ATTR-CM Competitive Position After Eplontersen Phase 3 Failure: The primary endpoint failure removes eplontersen as a ATTR-CM market contender, creating competitive void benefiting Alnylam and BridgeBio. * Both Companies Retain Buy-Rated Analyst Support Despite Material Setbacks: Analyst communities at both companies maintained positive ratings, highlighting ongoing pipeline value beyond the specific setback programs. Beam Therapeutics (NASDAQ: BEAM) and Ionis Pharmaceuticals (NASDAQ: IONS) both faced material competitive and clinical setbacks in the same week, illustrating the idiosyncratic and simultaneous risks that can affect biotech investors holding diversified positions across the gene therapy and antisense oligonucleotide technology platforms. Beam Therapeutics tumbled nearly 9% following the July 8 arbitration ruling that awarded rival Prime Medicine the right to develop PM647 for alpha-1 antitrypsin deficiency - injecting competitive uncertainty into the BEAM-302 AATD program just as the stock had recently touched a 52-week high near $38. BofA maintained its Buy rating with a $47 target, characterizing the ruling's impact as narrow and keeping analytical focus on BEAM-302 pivotal execution and the anticipated BEAM-101 BLA filing by year-end 2026. The arbitration ruling is binding, removing the possibility of a legal reversal, but BofA's characterization of the impact as narrow reflects confidence that Beam's base editing technology advantages can sustain competitive differentiation even with Prime Medicine entering the AATD field. Ionis Pharmaceuticals suffered a more severe setback: the CARDIO-TTRansform Phase 3 trial of eplontersen in ATTR cardiomyopathy patients failed to meet the primary endpoint of reducing cardiovascular mortality and recurrent cardiovascular events versus placebo. William Blair analysts described the failure as "surprising" given prior evidence supporting the combination approach, and the miss was followed by broad price target cuts: Morgan Stanley lowered to $110, Jefferies and Barclays each lowered to $90, and Citigroup (NYSE: C) lowered to $100 - though all maintained Buy or Overweight ratings reflecting confidence in the broader Ionis pipeline. The competitive beneficiaries of the Ionis failure are significant. Alnylam Pharmaceuticals (NASDAQ: ALNY), whose Amvuttra is approved for ATTR-CM, and BridgeBio Pharma (NASDAQ: BBIO), whose Attruby is an approved competing therapy, both stand to capture the market share Ionis had been expected to contest. AstraZeneca (NASDAQ: AZN) also fell on the shared setback, reflecting its involvement in the eplontersen development program. The simultaneous occurrence of competitive and clinical setbacks at two prominent biotech companies in the same week underscores the idiosyncratic and non-correlated nature of biotech investment risk - a reminder that portfolio-level biotech exposure requires diversification across programs and companies to manage the event-driven volatility that defines the sector. FAQs. Q: What are the key differences between Beam's and Ionis's setbacks? A: Beam Therapeutics' (NASDA Q: Which biotech companies benefit from Ionis's eplontersen Phase 3 failure? A: Alnylam Pharmaceuticals (NASDA Q: Why did analysts maintain Buy ratings at both companies despite the setbacks? A: Analysts maintained Buy ratings at both Beam Therapeutics (NASDA Download Free Report - Explore 3 Stock Ideas & Industry Insights Unlock 3 stock ideas and key industry insights in its free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice. All investments involve risk - consider independent advice before making any investment decisions. Disclaimer:
Prime Medicine has received New Zealand regulatory clearance for its Clinical Trial Application for PM577a, marking the first clinical authorisation for an in vivo Prime Editing therapy from the company. The therapy targets the H1069Q mutation in the ATP7B gene, the most prevalent Wilson Disease-causing allele in North America and Europe. The global Phase 1/2 open-label trial will evaluate safety, tolerability and efficacy of PM577a in adults and adolescents with Wilson Disease. Initial enrolment will focus on adults clinically stable on standard-of-care therapy. The study is expected to begin in the second half of 2026, with initial clinical data anticipated in 2027. Prime Medicine's shared lipid nanoparticle delivery platform may enable rapid expansion into additional Wilson Disease pathogenic variant populations, with the most advanced follow-on candidate targeting the R778L mutation common in East Asian populations.
Ocular Therapeutix and Prime Medicine represent contrasting investment opportunities in healthcare, balancing established commercial operations against early-stage gene therapy potential. Ocular Therapeutix develops bioresorbable hydrogel technology for eye treatments. Its lead product, Dextenza, treats post-surgical inflammation. The company generated $51.8 million revenue in FY 2025, down 18.7% year-over-year, with a net loss of $265.9 million. However, it maintains a strong current ratio of 15.4x and low debt-to-equity ratio of 0.1x. Prime Medicine focuses on Prime Editing technology for one-time genetic therapies. In FY 2025, revenue grew 55.3% to $4.6 million whilst net losses reached $201.1 million as it invests heavily in pipeline development. Both companies operate in high-risk sectors at different maturity stages, requiring investors to weigh commercial traction against transformative therapeutic potential.
Prime Medicine has reported first-quarter earnings per share of negative 28 cents, missing the consensus estimate of negative 25 cents. Revenue reached $856,000, slightly above the $844,220 estimate. The biotechnology company, which develops genetic medicines using Prime Editing technology, remains on track to file regulatory applications for PM577 in Wilson Disease during the first half of the year and for PM647 in alpha-1 antitrypsin deficiency mid-year. Initial data from both programmes is expected in 2027. Chief Executive Officer Allan Reine said Prime Medicine continues progressing towards a potential BLA filing for PM359, a one-time therapy for chronic granulomatous disease. Last month, the company appointed Svetlana Makhni as Chief Financial Officer to oversee financial operations and strategy.
Prime Medicine has raised its cash position to $149.2 million as of 31 March 2026, providing runway into 2027. The gene editing company remains on track to file regulatory applications for PM577 in Wilson Disease in the first half of 2026 and for PM647 in alpha-1 antitrypsin deficiency mid-year, with initial clinical data expected in 2027. The company continues regulatory dialogue with the FDA towards a potential biologics licence application filing for PM359 in chronic granulomatous disease. First quarter 2026 research and development expenses decreased to $34.1 million from $40.6 million year-over-year, whilst general and administrative expenses rose to $17.4 million from $13.3 million, primarily due to arbitration-related legal costs. Prime Medicine appointed Svetlana Makhni as chief financial officer in April 2026.